Treatment of haemophilia A and B and von Willebrand’s disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment-Reference-Cited by-同舟云学术

Treatment of haemophilia A and B and von Willebrand’s disease: summary and conclusions of a systematic review as part of a Swedish health-technology assessment

Published:2011-12-12 Issue:2 Volume:18 Page:158-165
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

BERNTORP E.,ASTERMARK J.,BAGHAEI F.,BERGQVIST D.,HOLMSTRÖM M.,LJUNGBERG B.,NORLUND A.,PALMBLAD J.,PETRINI P.,STIGENDAL L.,SÄWE J.

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2011.02723.x/fullpdf

Reference35 articles.

1. Hemophilia A and B and von Willebrand Disease - a systematic review (SBU) 2011 http://sbu.se/.AccessedSeptember20,2011

2. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group;Lusher;N Engl J Med,1993

3. A multicenter study of recombinant factor VIII (Recombinate) in previously treated patients with hemophilia A. The Recombinate Previously Treated Patient Study Group;White;Thromb Haemost,1997

4. A multicenter pharmacosurveillance study for the evaluation of the efficacy and safety of recombinant factor VIII in the treatment of patients with hemophilia A. German Kogenate Study Group;Aygoren-Pursun;Thromb Haemost,1997

5. Clinical evaluation of B-domain deleted recombinant factor VIII in previously untreated patients;Courter;Semin Hematol,2001

Cited by 35 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Augmented Degradation of Factors VIII and IX in the Intermittent Movement State;International Journal of Molecular Sciences;2023-06-27

2. Emergent Reversal of Antithrombotics and Treatment of Life-Threatening Bleeding from Coagulopathies: A Clinical Review;The Journal of Emergency Medicine;2022-07

3. Comparison of single subject and population‐based pharmacokinetics for optimizing prophylaxis with simoctocog alfa in patients with haemophilia A;Haemophilia;2021-05-09

4. Consenso de hemofilia en México;Gaceta de M�xico;2021-04-09

5. Burden on parents of children with haemophilia: The impact of sociodemographic and child's medical condition;Journal of Clinical Nursing;2019-09-03